Postoperative prognosis in craniopharyngioma with respect to cardiovascular mortality, survival, and tumor recurrence

J Clin Endocrinol Metab. 1998 Nov;83(11):3897-904. doi: 10.1210/jcem.83.11.5240.

Abstract

Specific causes of death, survival, and recurrence rates were assessed in a cohort of 60 patients who had undergone surgery for craniopharyngioma between 1951 and 1988. Compared to the general population, the standardized mortality ratio (SMR) was increased [5.55; 95% confidence interval (CI), 3.68-8.22], and it was higher among females (SMR, 11.4) than males (SMR, 4.79). The risk of cardio- and cerebrovascular mortality (SMR, 3.21; 95% CI, 1.29-6.61) was also enhanced. The cumulative survival rates 10 and 15 yr after the initial operation were 68% (95% CI 54-78) and 59% (95% CI 30-63), respectively. A multivariate survival analysis adjusting for age showed a protective effect of radiotherapy (hazard ratio, 0.3; 95% CI, 0.1-0.8) and an increased risk of death after recurrence (hazard ratio, 4.4; 95% CI, 1.4-14), but no obvious effect of radicality at surgery. However, when patients who had died within 6 months after surgery were excluded, no significant protective effect of radiotherapy remained. The cumulative frequency of recurrence after 10 yr was 33% (95% CI, 22-48%), and that after 15 yr was 40% (95% CI, 28-56%). The incidence of recurrence did not differ significantly with respect to age, radicality at surgery, or postoperative radiotherapy. The determinants for long term outcome in patients with craniopharyngioma are interrelated in a complex way, which calls for strict selection criteria in follow-up studies and the use of multivariate statistical models.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cardiovascular Diseases / etiology
  • Cardiovascular Diseases / mortality*
  • Combined Modality Therapy
  • Craniopharyngioma / complications
  • Craniopharyngioma / mortality
  • Craniopharyngioma / surgery*
  • Female
  • Humans
  • Incidence
  • Male
  • Neoplasm Recurrence, Local / mortality*
  • Pituitary Neoplasms / complications
  • Pituitary Neoplasms / mortality
  • Pituitary Neoplasms / surgery*
  • Postoperative Period
  • Prognosis
  • Retrospective Studies
  • Risk Factors
  • Survival Rate
  • Treatment Outcome